LIB takes aim at cholesterol market with new PCSK9 option LIB Therapeutics has won FDA approval for a once-monthly cholesterol drug, Lerochol, that it says offers ease-of-use advantages over rivals.

Privately-held drug developer #LIBTherapeutics has claimed #FDA approval for a new once-monthly #PCSK9inhibitor – Lerochol – that can be used to reduce #cholesterol levels.

pharmaphorum.com/news/lib-tak...